Skip to main content
. 2017 Oct 10;14(6):7549–7556. doi: 10.3892/ol.2017.7164

Figure 2.

Figure 2.

PFS according to the changes in CEA and CA15-3 levels at the end of the second therapeutic cycle in the 76 patients with non-assessable lesions. Kaplan-Meier graphs indicating the percentage of patients with PFS based on the changes in (A) CEA and (B) CA15-3 levels following the second cycle of chemotherapy. PFS, progression-free survival; CEA, carcinoembryonic antigen; CA15-3, carbohydrate antigen 15-3.